



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Implications of extracellular matrix production by adipose tissue-derived stem cells for development of wound healing therapies

Hyldig, Kathrine; Riis, Simone; Pennisi, Cristian Pablo; Zachar, Vladimir; Fink, Trine

Published in:
International Journal of Molecular Sciences

DOI (link to publication from Publisher):
[10.3390/ijms18061167](https://doi.org/10.3390/ijms18061167)

Creative Commons License
CC BY 4.0

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Hyldig, K., Riis, S., Pennisi, C. P., Zachar, V., & Fink, T. (2017). Implications of extracellular matrix production by adipose tissue-derived stem cells for development of wound healing therapies. *International Journal of Molecular Sciences*, 18(6), [1167]. <https://doi.org/10.3390/ijms18061167>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- ? You may not further distribute the material or use it for any profit-making activity or commercial gain
- ? You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.



Review

Implications of Extracellular Matrix Production by Adipose Tissue-Derived Stem Cells for Development of Wound Healing Therapies

Kathrine Hyldig, Simone Riis, Cristian Pablo Pennisi, Vladimir Zachar and Trine Fink *

Laboratory for Stem Cell Research, Department of Health Science and Technology, Aalborg University, 9220 Aalborg, Denmark; kha12@student.aau.dk (K.H.); sriis@hst.aau.dk (S.R.); cpennisi@hst.aau.dk (C.P.P.); vlaz@hst.aau.dk (V.Z.)

* Correspondence: trinef@hst.aau.dk; Tel.: +45-9940-7550

Academic Editor: Allison Cowin

Received: 3 April 2017; Accepted: 26 May 2017; Published: 31 May 2017

Abstract: The synthesis and deposition of extracellular matrix (ECM) plays an important role in the healing of acute and chronic wounds. Consequently, the use of ECM as treatment for chronic wounds has been of special interest—both in terms of inducing ECM production by resident cells and applying ex vivo produced ECM. For these purposes, using adipose tissue-derived stem cells (ASCs) could be of use. ASCs are recognized to promote wound healing of otherwise chronic wounds, possibly through the reduction of inflammation, induction of angiogenesis, and promotion of fibroblast and keratinocyte growth. However, little is known regarding the importance of ASC-produced ECM for wound healing. In this review, we describe the importance of ECM for wound healing, and how ECM production by ASCs may be exploited in developing new therapies for the treatment of chronic wounds.

Keywords: adipose stem cells; ASCs; extracellular matrix; wound healing

1. Introduction

Wound healing is a dynamic and well-orchestrated process with both molecular and cellular events. When for some reason the wound healing process is perturbed, the wounds may become chronic, with concomitant alterations in the microenvironment leading to prolonged inflammation, ischemia, dysfunctional extracellular matrix (ECM), and lack of re-epithelialization [1]. Traditional wound healing therapies are often not sufficient, so there is considerable interest in developing novel more efficient therapies. Among the novel strategies that are being explored, the use of adipose tissue-derived stem/stromal cells (ASCs) appears to be very promising, judging from animal studies [2] and early clinical studies [3]. The ASCs are derived from the so-called stromal vascular fraction of adipose tissue [4,5], which is a rather heterogeneous population. However, after expansion for just a few passages, the ASCs converge towards a common phenotype comprised of fewer, perhaps functionally distinct subtypes [6,7].

While it is still not clear how the ASCs mediate their effect, they have been shown to have immunomodulatory and proangiogenic properties, the ability to promote keratinocyte and fibroblast growth, as well as ability to reduce tissue scarring [8–13]. However, less is known about the putative effect of ASCs on the ECM of the chronic wounds. Consequently, in this review we will outline the role of ECM in wound healing, describe what is known regarding ASCs' effect on ECM, and speculate on how ASC-derived ECM may be exploited in novel wound healing therapies.

2. The ECM of the Skin

In human skin, the ECM contains both fibrous proteins and ground substance. The fibrous proteins comprise collagens, elastin, and fibronectin, and provide a three-dimensional scaffold upon which both individual cells and the vascular network are supported or anchored. The most abundant fibrous protein in the human skin is collagen I, with collagen III and collagen V representing only minor proportions of the total collagen [14]. During pathological conditions such as scar formation, the composition and structure of collagen fibers are altered [15]. The ground substance of the ECM contains proteoglycans and glycosaminoglycans, and surround the fibrous proteins as a jelly-like substance which provides hydration to the skin due to the strong hydrophilic characteristics.

Initially, ECM was thought to function only as structural support for the cells; however, it has become clear that the ECM plays a pivotal role in the regulation of cell behavior both under normal conditions and during wound healing [16,17]. The ECM regulates cell behavior through molecular signaling primarily mediated by integrins (a family of cell surface receptors), and it has been shown that these signals are involved in determining whether the cells proliferate, differentiate, or undergo apoptosis [18]. Among the resident skin cells that express integrins—and thus may be subjected to modulation by the ECM—are fibroblasts and keratinocytes [19]. In addition, proteins in the ECM modulate the activity of growth factors and cytokines such as platelet-derived growth factor (PDGF) and transforming growth factor- β (TGF- β), produced by activated platelets and macrophages, respectively [20,21]. Thus, the ECM functions as a reservoir by protecting the growth factors from degradation and controlling their release [22].

ECM homeostasis is partly controlled by the activity of matrix metalloproteinases (MMPs) and their counterpart, tissue inhibitors of metalloproteinases (TIMPs). The MMPs are mainly secreted by keratinocytes, fibroblasts, and endothelial cells [23], and TIMPs by—among others—mesenchymal stem cells (MSCs), keratinocytes, and fibroblasts [24,25]. Thus, the balance between MMPs and TIMPs is important for ECM remodeling, cell signaling, and cell migration [26], and it has been suggested that a high MMP/TIMP ratio could be a biomarker of non-healing wounds [27].

3. Role of ECM for Wound Healing

Acute wounds normally heal in four overlapping phases: hemostasis, inflammation, proliferation, and remodeling (Figure 1) [17,28,29]. Hemostasis occurs immediately after the injury, and is characterized by the activation and aggregation of platelets into the wounded area followed by the deposition of fibronectin and fibrin from the blood plasma. The activated platelets help initiate the inflammatory phase through the secretion of PDGF, which is important for the migration of macrophages and neutrophils to the wounded area [20], and TGF- β , which plays a major role in the transformation of monocytes to macrophages [21]. The stimulation of macrophages results in the development of polarized phenotypes termed classically activated (M1) macrophages that secrete pro-inflammatory cytokines and predominate during early wound healing and alternatively activated (M2) macrophages that are associated with a wound healing anti-inflammatory profile and which predominate in the later stages when inflammation abates and tissue undergoes remodeling [30,31].




Figure 1. The phases of normal wound healing. Wound healing normally progresses through a tightly orchestrated process that is usually described as having four overlapping phases. During hemostasis, a platelet plug is formed and growth factors are secreted. The inflammatory phase has two stages. The initial stage, where neutrophils and pro-inflammatory M1 macrophages prevail, and a second stage characterized by the presence of anti-inflammatory M2 macrophages. During the proliferation phase, fibroblasts proliferate and synthesize extracellular matrix (ECM), new vessels are formed, and keratinocytes re-epithelialize the surface of the wound. In the final remodeling stage, the composition of the ECM is altered through degradation and resynthesis. PDGF: platelet-derived growth factor; TGF- β : transforming growth factor- β .

During the proliferation phase of wound healing, fibroblasts migrate to the wounded area where they proliferate and initiate ECM synthesis [32]. The temporary matrix of fibrin and fibronectin is replaced by the collagen matrix, enriched in proteoglycans, glycosaminoglycans, and glycoproteins, forming a granulation tissue. Subsequently, the abundant extracellular matrix accumulates, supporting cell migration. In response to the newly-synthesized ECM, endothelial cells migrate into the wound and initiate the process of angiogenesis to restore the circulation in the damaged area [33]. The wound environment is characterized by low oxygen supply, regulating the process of angiogenesis through hypoxia-inducible factor-1 (HIF-1) [34]. Additionally, the secreted growth factors basic fibroblast growth factor (bFGF), TGF- β , and vascular endothelial growth factor (VEGF) stimulate the angiogenic activity [35]. Concurrently, keratinocytes migrate from the basement membrane towards the wound edge and close the wound. The migration of keratinocytes is dependent on basement membrane degradation, facilitated by MMPs [36].

In the remodeling phase, fibroblasts transform into myofibroblasts and contract the wound area [37]. Remodeling of the granulation tissue is characterized by the synthesis and breakdown of collagen, regulated by the MMPs and TIMPs [38].

When the normal progression through the different phases of wound healing is perturbed as described above, the wounds may become chronic. It appears that non-healing wounds remain in a transition state between the inflammation and proliferation phases and proliferative and remodeling phases become impaired [39] (Figure 2, left panel). It is not clear what causes the prolonged inflammation; however, macrophages in chronic wounds fail to switch from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype [40].

Furthermore, in mouse models of wound healing, there was a correlation between the presence of M2 macrophages, the resolution of inflammation, and wound healing, suggesting an important role of the polarization from M1 to M2 macrophages during the process of wound healing [41,42]. Interestingly, a switch in phenotype towards a more anti-inflammatory or pro-healing type has also been documented for Th1/Th2 cells and MSCs [43,44], which are possibly recruited to the site of injury from the bone marrow [45].

As wounds become chronic, the ECM homeostasis of the wound area is affected. Indeed, chronic wound fibroblasts are unresponsive to the stimulatory effect of TGF- β on collagen synthesis when compared to normal skin fibroblasts [46]. In addition, proteolytic enzymes involved in ECM degradation are dysregulated in chronic wounds, with increased expression of MMP-1, MMP-2, MMP-3, MMP-8, and MMP-9 [47,48] and decreased expression of the MMP inhibitor TIMP-2, leading to

excessive proteolysis of the ECM [48]. As the balance between ECM synthesis and degradation is impaired, the ECM becomes dysfunctional in terms of supporting cell migration and proliferation as well as angiogenesis [49].




Figure 2. Characteristics of chronic wounds and the relevant regenerative effects of ASCs on these. Chronic wounds appear to be unable to progress from the inflammatory phase of normal wound healing and to have impaired proliferation and remodeling phases (**left panel**). The ASCs have several regenerative characteristics that may lead to the wound progression from the inflammatory phase and through the proliferation and remodeling phases (**right panel**). ASC: adipose tissue-derived stem/stromal cells; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase; VEGF: vascular endothelial growth factor.

4. Using Adipose Stem Cells to Treat Chronic Wounds

The conventional treatment strategy for wound healing is based on wound bed preparation using tissue debridement, antibiotics, anti-inflammatory drugs, the restoration of moisture balance, and/or acceleration of epithelization by growth factor therapy [50,51]. Although these treatment options accelerate the wound healing process in many cases, many wounds are resistant to the current treatment options and more efficient methods are needed [49].

Recently, stem cell therapy has emerged as a novel approach for chronic wound healing. So far, most data is from studies using bone marrow-derived MSCs (BM-MSCs). However, as ASCs and BM-MSCs share numerous biological properties, much of the knowledge regarding BM-MSCs can be directly applied to the ASCs [52]. It has also become apparent the vastly higher numbers of ASCs than BM-MSCs can be obtained in a short time frame [52]. Thus, as procedures for the isolation and expansion of ASCs for clinical use have been optimized [53], ASCs are emerging as the most promising candidate for stem cell-based therapies for chronic wounds.

In the chronic wound environment, *in vitro* and *in vivo* studies suggest that the ASCs may be able to discontinue the prolonged inflammation phase and restore the progression through the phases of proliferation and remodeling (Figure 2, right panel). In terms of effects on the inflammatory processes, it is well known that ASCs may influence the functional characteristics and cytokine profile of T-, B-, and dendritic cells [54–56]. Notably, ASCs have also been shown to be able to induce a conversion of the macrophage phenotype from the pro-inflammatory M1 associated with chronic wounds to the anti-inflammatory and wound healing M2 phenotype [57,58]. During the proliferation phase, secreted factors from ASCs enhance several fibroblast characteristics, such as cell proliferation, migration and, importantly, the synthesis of collagen and other ECM proteins [59–61]. Furthermore, ASCs have been demonstrated to inhibit ECM degradation through the increased binding of MMPs and secretion of TIMPs [24]. The ability of ASCs to promote new vessel growth is also relevant to wound healing [62]. Finally, *in vitro* studies suggest that ASCs may promote re-epithelialization through modulation of keratinocytes in terms of promoting their proliferation and migration, but more studies are needed to confirm if this also holds true for chronic wounds [11,63].

To potentiate the wound healing effects of ASCs, the possibility of pre-conditioning the cells during *in vitro* expansion prior to clinical use has been suggested. In particular, the use of hypoxic culture appears interesting, as several of the wound healing properties of ASCs appear to be enhanced [64,65]. Significantly, it was recently found that hypoxic culture of ASCs altered their expression profile of several proteins related to ECM structure and function [66]. However, more data is needed to determine if the hypoxic potentiation of the regenerative properties of the ASCs *in vitro* can be translated into an enhanced effect *in vivo*.

5. ECM-Based Scaffolds for Wound Therapy

An alternative approach to using cells for wound therapy is to use acellular ECM. Acellular ECM-based scaffolds derived from natural tissues have been successfully applied in various preclinical and clinical settings for the treatment of severe wounds. These natural scaffolds appear to mediate tissue regeneration through a process known as constructive remodeling, in which the diverse ECM components orchestrate a process of scarless tissue repair [67]. There are various commercially available ECM-derived materials that are routinely used for the treatment of burns and chronic wounds, including materials obtained by the decellularization of animal tissues, such as porcine or bovine skin [68,69], or from allogeneic human skin [70]. A more detailed review of the variety of decellularized ECM scaffolds that are currently available for clinical use can be found in the literature [71]. Despite the relatively high success rates associated with these materials, some issues may still appear, such as sustained inflammatory responses and incomplete healing due to poor integrity of the native ECM molecules after decellularization [72]. In addition, xenogeneic ECM components may cause adverse host immune responses, and there is a risk of pathogen transfer [73]. To avoid these risks and the limitations associated with the supply of allogeneic human tissues, cell cultures have recently emerged as viable alternatives for the fabrication of ECM scaffolds. Depending on the cell type used for ECM synthesis, it is possible to fabricate ECM scaffolds containing specific proteins and morphogens that appear during early tissue development and which are associated with enhanced wound healing [74]. In particular, matrices derived from stem cells have shown promise as scaffolds for various tissue engineering and regenerative medicine applications, including regeneration of cartilage [75], bone [76], and neural tissue [77]. Surprisingly, despite the beneficial

properties of BM-MSCs or ASCs in the context of wound healing therapies, little is known regarding the use of stem cell ECM for wound healing applications. In this context, MSCs may possess a relative advantage over terminally differentiated skin fibroblasts, as they have shown an increased capacity to synthesize proteins involved in extracellular matrix, morphogenesis, and development [78,79]. The predominant upregulation of genes such as fibronectin (*FN1*) and extracellular matrix protein 2 (*ECM2*) found in MSCs suggests that the ECM derived from these cells may enhance wound healing by promoting matrix deposition and cell adhesion [78]. Accordingly, comprehensive proteomic analysis of ECM derived from MSCs has revealed an enrichment of structural proteins, including collagen I, VI, and XII, which together with an increased presence of MMPs indicates a highly dynamic matrix turnover [79]. Furthermore, MSC-derived ECM is also enriched in proteoglycans such as perlecan and hyaluronan, and glycoproteins such as fibronectin, tenascin-C, fibulin-1, and thrombospondin-1 [79]. Overall, these components of the ECM may contribute to the different phases of wound healing by supporting integrin-mediated cell adhesion and signaling, cell migration, and proliferation. In addition, decellularized stem cell ECM has demonstrated a significant angiogenic potential, which has been evidenced through the activation of endothelial cells [80]. An additional advantage of using stem cell cultures is the possibility of microenvironmental preconditioning of the cells during the fabrication process to tailor specific biological or biophysical functionalities in the scaffold that may promote wound healing [81]. In ASCs, in vitro ECM production and assembly has been shown to be controlled by mechanical and topographical cues from the microenvironment [82,83].

Decellularized ECM-scaffolds may be also used as platforms for cell delivery. It has been hypothesized that ASCs might have a better survival rate and reduce scar formation when administrated in combination with ECM-components [84]. Such a co-delivery could be implemented either using a patch of ECM seeded with ASCs [84] or delivering the ASCs in a fibrin spray glue.

In summary, although fabrication of ECM scaffolds using ASC cultures or co-delivery of ASCs and ECM represent novel concepts that may offer several comparative advantages for wound healing applications, the knowledge in this field is still scarce, and more efforts are needed to further develop these approaches into a clinical reality.

Acknowledgments: This work has been supported by a grant by the Obelske Family Foundation to Trine Fink.

Author Contributions: All authors have contributed to the concept, draft and final revision of the paper.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the writing of the manuscript, and in the decision to publish this review.

Abbreviations

ASC	Adipose stem cell/adipose stromal cell
bFGF	Basic fibroblast growth factor
BM-MSC	Bone marrow-derived mesenchymal stem cell
ECM	Extracellular matrix
HIF-1	Hypoxia-inducible factor 1
MSC	Mesenchymal stem cell
MMP	Matrix metalloprotease
PDGF	Platelet-derived growth factor
TGF- β	Transforming growth factor-beta
TIMP	Tissue inhibitor of metalloproteases
VEGF	Vascular endothelial growth factor

References

1. Eming, S.A.; Martin, P.; Tomic-Canic, M. Wound repair and regeneration: Mechanisms, signaling, and translation. *Sci. Transl. Med.* **2014**, *6*, 265sr6. [[CrossRef](#)] [[PubMed](#)]

2. Huang, S.-P.; Huang, C.-H.; Shyu, J.-F.; Lee, H.-S.; Chen, S.-G.; Chan, J.Y.-H.; Huang, S.-M. Promotion of wound healing using adipose-derived stem cells in radiation ulcer of a rat model. *J. Biomed. Sci.* **2013**, *20*, 51. [[CrossRef](#)] [[PubMed](#)]
3. Cerqueira, M.T.; Pirraco, R.P.; Marques, A.P. Stem Cells in Skin Wound Healing: Are We There Yet? *Adv. Wound Care* **2016**, *5*, 164–175. [[CrossRef](#)] [[PubMed](#)]
4. Zuk, P.A.; Zhu, M.; Mizuno, H.; Huang, J.; Futrell, J.W.; Katz, A.J.; Benhaim, P.; Lorenz, H.P.; Hedrick, M.H. Multilineage cells from human adipose tissue: Implications for cell-based therapies. *Tissue Eng.* **2001**, *7*, 211–228. [[CrossRef](#)] [[PubMed](#)]
5. Zachar, V.; Rasmussen, J.G.; Fink, T. Isolation and growth of adipose tissue-derived stem cells. *Methods Mol. Biol.* **2011**, *698*, 37–49. [[PubMed](#)]
6. Riis, S.; Nielsen, F.M.; Pennisi, C.P.; Zachar, V.; Fink, T. Comparative Analysis of Media and Supplements on Initiation and Expansion of Adipose-Derived Stem Cells. *Stem Cells Transl. Med.* **2016**, *5*, 314–324. [[CrossRef](#)] [[PubMed](#)]
7. Nielsen, F.M.; Riis, S.E.; Andersen, J.I.; Lesage, R.; Fink, T.; Pennisi, C.P.; Zachar, V. Discrete adipose-derived stem cell subpopulations may display differential functionality after in vitro expansion despite convergence to a common phenotype distribution. *Stem Cell Res. Ther.* **2016**, *7*, 177. [[CrossRef](#)] [[PubMed](#)]
8. Mattar, P.; Bieback, K. Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells. *Front. Immunol.* **2015**, *6*, 560. [[CrossRef](#)] [[PubMed](#)]
9. Rasmussen, J.G.; Frøbert, O.; Holst-Hansen, C.; Kastrup, J.; Baandrup, U.; Zachar, V.; Fink, T.; Simonsen, U. Comparison of human adipose-derived stem cells and bone marrow-derived stem cells in a myocardial infarction model. *Cell Transplant.* **2014**, *23*, 195–206. [[CrossRef](#)] [[PubMed](#)]
10. Rasmussen, J.G.; Riis, S.E.; Frøbert, O.; Yang, S.; Kastrup, J.; Zachar, V.; Simonsen, U.; Fink, T. Activation of Protease-Activated Receptor 2 Induces VEGF Independently of HIF-1. *PLoS ONE* **2012**, *7*, e46087. [[CrossRef](#)] [[PubMed](#)]
11. Riis, S.; Newman, R.; Ipek, H.; Andersen, J.I.; Kuninger, D.; Boucher, S.; Vemuri, M.C.; Pennisi, C.P.P.; Zachar, V.; Fink, T. Hypoxia enhances the wound-healing potential of adipose-derived stem cells in a novel human primary keratinocyte-based scratch assay. *Int. J. Mol. Med.* **2017**, *39*, 587–594. [[CrossRef](#)] [[PubMed](#)]
12. Shafy, A.; Fink, T.; Zachar, V.; Lila, N.; Carpentier, A.; Chachques, J.C. Development of cardiac support bioprostheses for ventricular restoration and myocardial regeneration. *Eur. J. Cardiothorac. Surg.* **2013**, *43*, 1211–1219. [[CrossRef](#)] [[PubMed](#)]
13. Lee, E.Y.; Xia, Y.; Kim, W.-S.; Lila, N.; Carpentier, A.; Chachques, J.C. Hypoxia-enhanced wound-healing function of adipose-derived stem cells: Increase in stem cell proliferation and up-regulation of VEGF and bFGF. *Wound Repair Regen.* **2009**, *17*, 540–547. [[CrossRef](#)] [[PubMed](#)]
14. Smith, L.T.; Holbrook, K.A.; Madri, J.A. Collagen types I, III, and V in human embryonic and fetal skin. *Am. J. Anat.* **1986**, *175*, 507–521. [[CrossRef](#)] [[PubMed](#)]
15. Verhaegen, P.D.H.M.; van Zuijlen, P.P.M.; Pennings, N.M.; van Marle, J.; Niessen, F.B.; van der Horst, C.M.A.M.; Middelkoop, E. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis. *Wound Repair Regen.* **2009**, *17*, 649–656. [[CrossRef](#)] [[PubMed](#)]
16. Eckes, B.; Nischt, R.; Krieg, T. Cell-matrix interactions in dermal repair and scarring. *Fibrogenesis Tissue Repair* **2010**, *3*, 4. [[CrossRef](#)] [[PubMed](#)]
17. Hodde, J.P.; Johnson, C.E. Extracellular matrix as a strategy for treating chronic wounds. *Am. J. Clin. Dermatol.* **2007**, *8*, 61–66. [[CrossRef](#)] [[PubMed](#)]
18. Giancotti, F.G.; Ruoslahti, E. Integrin Signaling. *Science* **1999**, *285*, 1028–1033. [[CrossRef](#)] [[PubMed](#)]
19. Koivisto, L.; Heino, J.; Häkkinen, L.; Larjava, H. Integrins in Wound Healing. *Adv. Wound Care* **2014**, *3*, 762–783. [[CrossRef](#)] [[PubMed](#)]
20. Lynch, S.E.; Nixon, J.C.; Colvin, R.B.; Antoniades, H.N. Role of platelet-derived growth factor in wound healing: Synergistic effects with other growth factors. *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 7696–7700. [[CrossRef](#)] [[PubMed](#)]
21. Barrientos, S.; Stojadinovic, O.; Golinko, M.S.; Brem, H.; Tomic-Canic, M. PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing. *Wound Repair Regen.* **2008**, *16*, 585–601. [[CrossRef](#)] [[PubMed](#)]
22. Schultz, G.S.; Wysocki, A. Interactions between extracellular matrix and growth factors in wound healing. *Wound Repair Regen.* **2009**, *17*, 153–162. [[CrossRef](#)] [[PubMed](#)]

23. Martins, V.L.; Caley, M.; O'Toole, E.A. Matrix metalloproteinases and epidermal wound repair. *Cell Tissue Res.* **2013**, *351*, 255–268. [[CrossRef](#)] [[PubMed](#)]
24. Lozito, T.P.; Jackson, W.M.; Nesti, L.J.; Tuan, R.S. Human mesenchymal stem cells generate a distinct pericellular zone of MMP activities via binding of MMPs and secretion of high levels of TIMPs. *Matrix Biol.* **2014**, *34*, 132–143. [[CrossRef](#)] [[PubMed](#)]
25. Tandara, A.A.; Mustoe, T.A. MMP- and TIMP-secretion by human cutaneous keratinocytes and fibroblasts—Impact of coculture and hydration. *J. Plast. Reconstr. Aesthetic. Surg.* **2011**, *64*, 108–116. [[CrossRef](#)] [[PubMed](#)]
26. Nagase, H.; Visse, R.; Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc. Res.* **2006**, *69*, 562–573. [[CrossRef](#)] [[PubMed](#)]
27. Patel, S.; Maheshwari, A.; Chandra, A. Biomarkers for wound healing and their evaluation. *J. Wound Care* **2016**, *25*, 46–55. [[CrossRef](#)] [[PubMed](#)]
28. Olczyk, P.; Mecnier, Ł.; Komosinska-Vassev, K. The role of the extracellular matrix components in cutaneous wound healing. *BioMed Res. Int.* **2014**, *2014*, 747584. [[CrossRef](#)] [[PubMed](#)]
29. Hassan, W.U.; Greiser, U.; Wang, W. Role of adipose-derived stem cells in wound healing. *Wound Repair Regen.* **2014**, *22*, 313–325. [[CrossRef](#)] [[PubMed](#)]
30. Martinez, F.O.; Sica, A.; Mantovani, A.; Locati, M. Macrophage activation and polarization. *Front. Biosci.* **2008**, *13*, 453–461. [[CrossRef](#)] [[PubMed](#)]
31. Ferrante, C.J.; Leibovich, S.J. Regulation of Macrophage Polarization and Wound Healing. *Adv. Wound Care* **2012**, *1*, 10–16. [[CrossRef](#)] [[PubMed](#)]
32. Pierce, G.F.; Mustoe, T.A.; Lingelbach, J.; Masakowski, V.R.; Griffin, G.L.; Senior, R.M.; Deuel, T.F. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. *J. Cell Biol.* **1989**, *109*, 429–440. [[CrossRef](#)] [[PubMed](#)]
33. Vorotnikova, E.; McIntosh, D.; Dewilde, A.; Zhang, J.; Reing, J.E.; Zhang, L.; Cordero, K.; Bedelbaeva, K.; Gourevitch, D.; Heber-Katz, E.; et al. Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo. *Matrix Biol.* **2010**, *29*, 690–700. [[CrossRef](#)] [[PubMed](#)]
34. Liu, Y.; Cox, S.R.; Morita, T.; Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. *Circ. Res.* **1995**, *77*, 638–643. [[CrossRef](#)] [[PubMed](#)]
35. Ucuzian, A.A.; Gassman, A.A.; East, A.T.; Greisler, H.P. Molecular mediators of angiogenesis. *J. Burn Care Res.* **2010**, *31*, 158–175. [[CrossRef](#)] [[PubMed](#)]
36. Caley, M.P.; Martins, V.L.C.; O'Toole, E.A. Metalloproteinases and Wound Healing. *Adv. Wound Care* **2015**, *4*, 225–234. [[CrossRef](#)] [[PubMed](#)]
37. Wu, M.; Ben Amar, M. Growth and remodelling for profound circular wounds in skin. *Biomech. Model. Mechanobiol.* **2015**, *14*, 357–370. [[CrossRef](#)] [[PubMed](#)]
38. Saarialho-Kere, U.K. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. *Arch. Dermatol. Res.* **1998**, *290*, S47–S54. [[CrossRef](#)] [[PubMed](#)]
39. Loots, M.A.M.; Lamme, E.N.; Zeegelaar, J.; Mekkes, J.R.; Bos, J.D.; Middelkoop, E. Differences in Cellular Infiltrate and Extracellular Matrix of Chronic Diabetic and Venous Ulcers Versus Acute Wounds. *J. Investig. Dermatol.* **1998**, *111*, 850–857. [[CrossRef](#)] [[PubMed](#)]
40. Sindrilaru, A.; Peters, T.; Wieschalka, S.; Baican, C.; Baican, A.; Peter, H.; Hainzl, A.; Schatz, S.; Qi, Y.; Schlecht, A.; et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. *J. Clin. Investig.* **2011**, *121*, 985–997. [[CrossRef](#)] [[PubMed](#)]
41. Mirza, R.; Koh, T.J. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. *Cytokine* **2011**, *56*, 256–264. [[CrossRef](#)] [[PubMed](#)]
42. Lucas, T.; Waisman, A.; Ranjan, R.; Roes, J.; Krieg, T.; Müller, W.; Roers, A.; Eming, S.A. Differential Roles of Macrophages in Diverse Phases of Skin Repair. *J. Immunol.* **2010**, *184*, 3964–3977. [[CrossRef](#)] [[PubMed](#)]
43. Park, J.E.; Barbul, A. Understanding the role of immune regulation in wound healing. *Am. J. Surg.* **2004**, *187*, S11–S16. [[CrossRef](#)]
44. Waterman, R.S.; Tomchuck, S.L.; Henkle, S.L.; Betancourt, A.M. A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype. *PLoS ONE* **2010**, *5*, e10088. [[CrossRef](#)] [[PubMed](#)]

45. Seppanen, E.; Roy, E.; Ellis, R.; Bou-Gharios, G.; Fisk, N.M.; Khosrotehrani, K. Distant Mesenchymal Progenitors Contribute to Skin Wound Healing and Produce Collagen: Evidence from a Murine Fetal Microchimerism Model. *PLoS ONE* **2013**, *8*, e62662. [[CrossRef](#)] [[PubMed](#)]
46. Hasan, A.; Murata, H.; Falabella, A.; Ochoa, S.; Zhou, L.; Badiavas, E.; Falanga, V. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. *J. Dermatol. Sci.* **1997**, *16*, 59–66. [[CrossRef](#)]
47. Lobmann, R.; Ambrosch, A.; Schultz, G.; Waldmann, K.; Schiweck, S.; Lehnert, H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. *Diabetologia* **2002**, *45*, 1011–1016. [[CrossRef](#)] [[PubMed](#)]
48. Subramaniam, K.; Pech, C.M.; Stacey, M.C.; Wallace, H.J. Induction of MMP-1, MMP-3 and TIMP-1 in normal dermal fibroblasts by chronic venous leg ulcer wound fluid. *Int. Wound J.* **2008**, *5*, 79–86. [[CrossRef](#)] [[PubMed](#)]
49. Demidova-Rice, T.N.; Hamblin, M.R.; Herman, I.M. Acute and impaired wound healing: Pathophysiology and current methods for drug delivery, part 1: Normal and chronic wounds: Biology, causes, and approaches to care. *Adv. Skin Wound Care* **2012**, *25*, 304–314. [[CrossRef](#)] [[PubMed](#)]
50. Schultz, G.S.; Sibbald, R.G.; Falanga, V.; Ayello, E.A.; Dowsett, C.; Harding, K.; Romanelli, M.; Stacey, M.C.; Teot, L.; Vanscheidt, W. Wound bed preparation: A systematic approach to wound management. *Wound Repair Regen.* **2003**, *11* (Suppl. S1), S1–S28. [[CrossRef](#)] [[PubMed](#)]
51. Ayello, E.A.; Dowsett, C.; Schultz, G.S.; Sibbald, R.G.; Falanga, V.; Harding, K.; Romanelli, M.; Stacey, M.; Teot, L.; Vanscheidt, W. TIME heals all wounds. *Nursing* **2004**, *34*, 36–42. [[CrossRef](#)] [[PubMed](#)]
52. Strioga, M.; Viswanathan, S.; Darinskas, A.; Slaby, O.; Michalek, J. Same or Not the Same? Comparison of Adipose Tissue-Derived versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells. *Stem Cells Dev.* **2012**, *21*, 2724–2752. [[CrossRef](#)] [[PubMed](#)]
53. Riis, S.; Zachar, V.; Boucher, S.; Vemuri, M.C.; Pennisi, C.P.; Fink, T. Critical steps in the isolation and expansion of adipose-derived stem cells for translational therapy. *Expert Rev. Mol. Med.* **2015**, *17*, e11. [[CrossRef](#)] [[PubMed](#)]
54. Baharlou, R.; Ahmadi-Vasmehjani, A.; Faraji, F.; Atashzar, M.R.; Khoubyari, M.; Ahi, S.; Erfanian, S.; Navabi, S.-S. Human adipose tissue-derived mesenchymal stem cells in rheumatoid arthritis: Regulatory effects on peripheral blood mononuclear cells activation. *Int. Immunopharmacol.* **2017**, *47*, 59–69. [[CrossRef](#)] [[PubMed](#)]
55. Anderson, P.; Gonzalez-Rey, E.; O'Valle, F.; Martin, F.; Oliver, F.J.; Delgado, M. Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function. *Stem Cells Int.* **2017**, *2017*, 1–15. [[CrossRef](#)] [[PubMed](#)]
56. Franquesa, M.; Mensah, F.K.; Huizinga, R.; Strini, T.; Boon, L.; Lombardo, E.; DelaRosa, O.; Laman, J.D.; Grinyó, J.M.; Weimar, W.; Betjes, M.G.H.; Baan, C.C.; Hoogduijn, M.J. Human Adipose Tissue-Derived Mesenchymal Stem Cells Abrogate Plasmablast Formation and Induce Regulatory B Cells Independently of T Helper Cells. *Stem Cells* **2015**, *33*, 880–891. [[CrossRef](#)] [[PubMed](#)]
57. Manning, C.N.; Martel, C.; Sakiyama-Elbert, S.E.; Silva, M.J.; Shah, S.; Gelberman, R.H.; Thomopoulos, S. Adipose-derived mesenchymal stromal cells modulate tendon fibroblast responses to macrophage-induced inflammation in vitro. *Stem Cell Res. Ther.* **2015**, *6*, 74. [[CrossRef](#)] [[PubMed](#)]
58. Lo Sicco, C.; Reverberi, D.; Balbi, C.; Ulivi, V.; Principi, E.; Pascucci, L.; Becherini, P.; Bosco, M.C.; Varesio, L.; Franzin, C.; Pozzobon, M.; Cancedda, R.; Tasso, R. Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization. *Stem Cells Transl. Med.* **2017**, *6*, 1018–1028. [[CrossRef](#)] [[PubMed](#)]
59. Zhao, J.; Hu, L.; Liu, J.; Gong, N.; Chen, L. The effects of cytokines in adipose stem cell-conditioned medium on the migration and proliferation of skin fibroblasts in vitro. *Biomed. Res. Int.* **2013**, *2013*, 578479. [[CrossRef](#)] [[PubMed](#)]
60. Hu, L.; Wang, J.; Zhou, X.; Xiong, Z.; Zhao, J.; Yu, R.; Huang, F.; Zhang, H.; Chen, L. Exosomes derived from human adipose mesenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts. *Sci. Rep.* **2016**, *6*, 32993. [[CrossRef](#)] [[PubMed](#)]
61. Na, Y.K.; Ban, J.-J.; Lee, M.; Im, W.; Kim, M. Wound healing potential of adipose tissue stem cell extract. *Biochem. Biophys. Res. Commun.* **2017**, *485*, 30–34. [[CrossRef](#)] [[PubMed](#)]

62. Rasmussen, J.G.; Frøbert, O.; Pilgaard, L.; Kastrup, J.; Simonsen, U.; Zachar, V.; Fink, T. Prolonged hypoxic culture and trypsinization increase the pro-angiogenic potential of human adipose tissue-derived stem cells. *Cytotherapy* **2011**, *13*, 318–328. [[CrossRef](#)] [[PubMed](#)]
63. Lee, S.H.; Jin, S.Y.; Song, J.S.; Seo, K.K.; Cho, K.H. Paracrine Effects of Adipose-Derived Stem Cells on Keratinocytes and Dermal Fibroblasts. *Ann. Dermatol.* **2012**, *24*, 136. [[CrossRef](#)] [[PubMed](#)]
64. Zachar, V.; Duroux, M.; Emmersen, J.; Rasmussen, J.G.; Pennisi, C.P.; Yang, S.; Fink, T. Hypoxia and adipose-derived stem cell-based tissue regeneration and engineering. *Expert Opin. Biol. Ther.* **2011**, *11*, 775–786. [[CrossRef](#)] [[PubMed](#)]
65. Choi, J.R.; Yong, K.W.; Wan Safwani, W.K.Z. Effect of hypoxia on human adipose-derived mesenchymal stem cells and its potential clinical applications. *Cell. Mol. Life Sci.* **2017**. [[CrossRef](#)] [[PubMed](#)]
66. Riis, S.; Stensballe, A.; Emmersen, J.; Pennisi, C.P.; Birkelund, S.; Zachar, V.; Fink, T. Mass spectrometry analysis of adipose-derived stem cells reveals a significant effect of hypoxia on pathways regulating extracellular matrix. *Stem Cell Res. Ther.* **2016**, *7*, 52. [[CrossRef](#)] [[PubMed](#)]
67. Brown, B.N.; Badylak, S.F. Extracellular matrix as an inductive scaffold for functional tissue reconstruction. *Transl. Res.* **2014**, *163*, 268–285. [[CrossRef](#)] [[PubMed](#)]
68. Feng, X.; Shen, R.; Tan, J.; Chen, X.; Pan, Y.; Ruan, S.; Zhang, F.; Lin, Z.; Zeng, Y.; Wang, X.; Lin, Y.; Wu, Q. The study of inhibiting systematic inflammatory response syndrome by applying xenogenic (porcine) acellular dermal matrix on second-degree burns. *Burns* **2007**, *33*, 477–479. [[CrossRef](#)] [[PubMed](#)]
69. Brigido, S.A.; Boc, S.F.; Lopez, R.C. Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: A pilot study. *Orthopedics* **2004**, *27*, s145–s149. [[PubMed](#)]
70. Yonehiro, L.; Burleson, G.; Sauer, V. Use of a new acellular dermal matrix for treatment of nonhealing wounds in the lower extremities of patients with diabetes. *Wounds Compend. Clin. Res. Pract.* **2013**, *25*, 340–344.
71. Parmaksiz, M.; Dogan, A.; Odabas, S.; Elçin, A.E.; Elçin, Y.M. Clinical applications of decellularized extracellular matrices for tissue engineering and regenerative medicine. *Biomed. Mater.* **2016**, *11*, 22003. [[CrossRef](#)] [[PubMed](#)]
72. Sun, W.Q.; Xu, H.; Sandor, M.; Lombardi, J. Process-induced extracellular matrix alterations affect the mechanisms of soft tissue repair and regeneration. *J. Tissue Eng.* **2013**, *4*, 204173141350530. [[CrossRef](#)] [[PubMed](#)]
73. Scobie, L.; Padler-Karavani, V.; Le Bas-Bernardet, S.; Crossan, C.; Blaha, J.; Matouskova, M.; Hector, R.D.; Cozzi, E.; Vanhove, B.; Charreau, B.; et al. Long-Term IgG Response to Porcine Neu5Gc Antigens without Transmission of PERV in Burn Patients Treated with Porcine Skin Xenografts. *J. Immunol.* **2013**, *191*, 2907–2915. [[CrossRef](#)] [[PubMed](#)]
74. Fitzpatrick, L.E.; McDevitt, T.C. Cell-derived matrices for tissue engineering and regenerative medicine applications. *Biomater. Sci.* **2015**, *3*, 12–24. [[CrossRef](#)] [[PubMed](#)]
75. Lu, H.; Hoshiba, T.; Kawazoe, N.; Koda, I.; Song, M.; Chen, G. Cultured cell-derived extracellular matrix scaffolds for tissue engineering. *Biomaterials* **2011**, *32*, 9658–9666. [[CrossRef](#)] [[PubMed](#)]
76. Zhang, Z.; Luo, X.; Xu, H.; Wang, L.; Jin, X.; Chen, R.; Ren, X.; Lu, Y.; Fu, M.; Huand, Y. Bone marrow stromal cell-derived extracellular matrix promotes osteogenesis of adipose-derived stem cells. *Cell Biol. Int.* **2015**, *39*, 291–299. [[CrossRef](#)] [[PubMed](#)]
77. Aizman, I.; Tate, C.C.; McGrogan, M.; Case, C.C. Extracellular matrix produced by bone marrow stromal cells and by their derivative, SB623 cells, supports neural cell growth. *J. Neurosci. Res.* **2009**, *87*, 3198–3206. [[CrossRef](#)] [[PubMed](#)]
78. Wagner, W.; Wein, F.; Seckinger, A.; Frankhauser, M.; Wirkner, U.; Krause, U.; Blake, J.; Schwager, C.; Eckstein, V.; Ansoorge, W.; et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp. Hematol.* **2005**, *33*, 1402–1416. [[CrossRef](#)] [[PubMed](#)]
79. Ragelle, H.; Naba, A.; Larson, B.L.; Zhou, F.; Prijčić, M.; Whittaker, C.A.; Del Rosario, A.; Langer, R.; Hynes, R.O. Comprehensive proteomic characterization of stem cell-derived extracellular matrices. *Biomaterials* **2017**, *128*, 147–159. [[CrossRef](#)] [[PubMed](#)]
80. Burns, J.S.; Kristiansen, M.; Kristensen, L.P.; Larsen, K.H.; Nielsen, M.O.; Christiansen, H.; Nehlin, J.; Andersen, J.S.; Kassem, M. Decellularized Matrix from Tumorigenic Human Mesenchymal Stem Cells Promotes Neovascularization with Galectin-1 Dependent Endothelial Interaction. *PLoS ONE* **2011**, *6*, e21888. [[CrossRef](#)] [[PubMed](#)]

81. Grenier, G.; Rémy-Zolghadri, M.; Larouche, D.; Gauvin, R.; Baker, K.; Bergeron, F.; Dupuis, D.; Langelier, E.; Rancourt, D.; Auger, F.A.; et al. Tissue reorganization in response to mechanical load increases functionality. *Tissue Eng.* **2005**, *11*, 90–100. [[CrossRef](#)] [[PubMed](#)]
82. Colazzo, F.; Sarathchandra, P.; Smolenski, R.T.; Chester, A.H.; Tseng, Y.T.; Czernususzka, J.T.; Yacoub, M.H.; Taylor, P.M. Extracellular matrix production by adipose-derived stem cells: Implications for heart valve tissue engineering. *Biomaterials* **2011**, *32*, 119–127. [[CrossRef](#)] [[PubMed](#)]
83. Foldberg, S.; Petersen, M.; Fojan, P.; Gurevich, L.; Fink, T.; Pennisi, C.P.; Zachar, V. Patterned poly(lactic acid) films support growth and spontaneous multilineage gene expression of adipose-derived stem cells. *Colloids Surf. B Biointerfaces* **2012**, *93*, 92–99. [[CrossRef](#)] [[PubMed](#)]
84. Lam, M.T.; Nauta, A.; Meyer, N.P.; Wu, J.C.; Longaker, M.T. Effective Delivery of Stem Cells Using an Extracellular Matrix Patch Results in Increased Cell Survival and Proliferation and Reduced Scarring in Skin Wound Healing. *Tissue Eng. Part A* **2013**, *19*, 738–747. [[CrossRef](#)] [[PubMed](#)]



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).